This study is looking at a new imaging method for people with pancreatic neuroendocrine tumors (a type of cancer that starts in the pancreas and has spread or cannot be removed by surgery). Researchers are using a special tracer called [18F]FluorThanatrace ([18F]FTT) with a PET/CT scan. This tracer helps them see how much of a protein called PARP-1 is present in the tumors. PARP-1 is involved in DNA repair, and understanding its levels might help find new ways to treat these tumors. The main goal is to measure how much [18F]FTT is taken up by the tumors. You can join if you are 18 or older and have a diagnosed metastatic or unresectable pancreatic neuroendocrine tumor that is at least 1.5 cm in size. The study plans to enroll 12 patients. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 12 participants. It is a pilot study to evaluate PARP-1 expression using a novel PET imaging agent.

What's involved

Participants will receive an intravenous injection of [18F]FluorThanatrace and undergo a whole-body PET CT scan, including dynamic imaging for 60 minutes and possibly a static scan up to 90 minutes later.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, [18F]FTT SUV in PanNETS, is measured at Baseline. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.